Company: RPTX
Filing Date: 2025-12-03
Form Type: PREM14A
Source: 0001193125-25-306948
Chunk: 47

Company: Repare Therapeutics Inc.
Filing Date: 2025-12-03
Form: PREM14A
Chunk 47
---
) the ability of the Company to retain key personnel; (v) potential adverse reactions or changes to business relationships resulting from the announcement or
completion of the Arrangement; (vi) continued availability of capital and financing and rating agency actions; (vii) legislative, regulatory and economic developments affecting the Company’s business; (viii) the accuracy of the
Company’s financial projections; (ix) general business, market and economic conditions; (x) certain restrictions during the pendency of the Arrangement that may impact the Company’s ability to pursue certain business
opportunities or strategic transactions; (xi) unpredictability and severity of catastrophic events, including but not limited to acts of

24

terrorism, pandemics, outbreaks of war or hostilities, as well as the Company’s response to any of the aforementioned factors; (xii) significant transaction costs associated with the
Transaction; (xiii) the possibility that the Arrangement may be more expensive to complete than anticipated, including as a result of unexpected factors or events; (xiv) competitive responses to the Arrangement; (xv) the risks and
uncertainties pertaining to the Company’s business, including those set forth in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with SEC on
March 3, 2025, under the heading “Risk Factors,” as updated in any subsequent Quarterly Reports on Form 10-Q and other documents the Company has filed or may file from time to time with the SEC, copies of which are or will be
available on the Company’s profile on EDGAR at www.sec.gov and on SEDAR+ at www.sedarplus.ca, and as otherwise disclosed from time to time on the Company’s EDGAR and SEDAR+ profiles.

These risks, as well as other risks associated with the Transaction, are more fully discussed in this Circular and Proxy Statement. While the
list of factors presented here is, and the list of factors presented in this Circular and Proxy Statement are, considered representative, no such list should be considered a complete statement of all potential risks and uncertainties. Unlisted
factors may present significant additional obstacles to the realization of forward-looking statements. Consequences of material differences in results as compared with those anticipated in the forward-looking statements could include, among other
things, business disruption, operational problems, financial loss, legal liability to third parties and similar risks, any of which could have a material impact on the Company